WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome, 2023 Hwang et al

AuroraNY said:
If anyone is going to be at the NIH Research Festival in September, there is apparently going to be a poster entitled "Chronic Fatigue Syndrome-associated gene WASF3 mediates immune abnormalities in mouse models."

The presenter is Ananya Ganguly, a visiting postdoctoral fellow in immunology, and the authors are Paul Hwang and others from the original WASF3 paper.


https://researchfestival.nih.gov/2026/posters-session
Click to expand...
That's really interesting. It's been a while since their first MECFS paper. Although Iirc someone said recently they were aware of a failed WASF3 replication attempt ?
 
I have not been on campus for about 15 years, but I seem to remember they had security protocols. Maybe I am misremembering, though. It may be worth a quick phone call - if only to be on the safe side.

And, yes, I'd like to know about what insights the poster has to offer, too.
 
We didn't specifically try to replicate this study but when we have done basic respirometry experiments on fibroblast lines with mitochondrial inhibitors and standard media we haven't seen differences as far as I am aware. I still hold this study as one of the few if only positive results and well conducted studies in this area but I personally moved on from this avenue of investigation (mitochondrial respiration as a primary driver) years ago

there is a bit of buzz around using different substrates or compounds which affect processes upstream of OXPHOS (upstream in terms of energy metabolism) which I think might be more interesting. especially relating to glutamine or lipid catabolism bc those tend to have broader signalling implications that have not been looked at as much
 
Last edited:
DMissa said:
We didn't specifically try to replicate this study but when we have done basic respirometry experiments on fibroblast lines with mitochondrial inhibitors and standard media we haven't seen differences as far as I am aware. I still hold this study as one of the few if only positive results and well conducted studies in this area but I personally moved on from this avenue of investigation (mitochondrial respiration as a primary driver) years ago

there is a bit of buzz around using different substrates or compounds which affect processes upstream of OXPHOS (upstream in terms of energy metabolism) which I think might be more interesting. especially relating to glutamine or lipid catabolism bc those tend to have broader signalling implications that have not been looked at as much
Click to expand...
Many thanks for the clarification! Yes, it sounded strange, as until now this appears to be the only positive ME/CFS study conducted properly, and a failed replication attempt would likely already be known.

Let’s see what the results of his planned 2027 trial using an FDA-approved repurposed drug targeting ER stress will show.

Very Intriguing case beside F&M Dara and SequenceME!
 
Last edited:
Lisan_Al_Ghaib_87 said:
Many thanks for the clarification! Yes, it sounded strange, as until now this appears to be the only positive ME/CFS study conducted properly, and a failed replication attempt would likely already be known.

Let’s see what the results of his planned 2027 trial using an FDA-approved repurposed drug targeting ER stress will show.

Very Intriguing case beside F&M Dara and SequenceME!
Click to expand...
Which drug is going to trialed for repurposing for ER stress.
 
V.R.T. said:
If WASF3 was involved in causing symptoms in MECFS, wouldn't it have come up in DecodeME?
Click to expand...
Even though thats very scientifical question which I cannot answer it, doing a fast research on the internet seems that WASF3 is primarily expressed and active in the nervous system under normal physiological conditions thus maybe there is still a conection with the relevant locki indendified in their study.

Input from the "genetics A-Team department" of the forum will be very much appreciated.
 
Lisan_Al_Ghaib_87 said:
Many thanks for the clarification! Yes, it sounded strange, as until now this appears to be the only positive ME/CFS study conducted properly, and a failed replication attempt would likely already be known.

Let’s see what the results of his planned 2027 trial using an FDA-approved repurposed drug targeting ER stress will show.

Very Intriguing case beside F&M Dara and SequenceME!
Click to expand...
If you are looking for a currently available remedy for ER stress, @mariovitali has some information about TUDCA being helpful on twitter

 
You must log in or register to reply here.
Back
Top Bottom